Why Hims & Hers Health, Inc. (HIMS) Skyrocketed on Friday

We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other Friday’s top performers.

The stock market finished the trading week in the green territory as investors looked past the series of mixed corporate earnings performance and inflation worries, amid the easing trade tensions between the US and China.

The Dow Jones climbed by 0.78 percent, while the S&P 500 and the tech-heavy Nasdaq grew by 0.70 percent and 0.52 percent, respectively.

Beyond major indices, 10 companies—predominantly Bitcoin miners and quantum computing firms—registered a strong finish, thanks to fresh corporate developments boosting investor appetite.

In this article, we name Friday’s 10 top performers and detail the reasons behind their gains.

To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume.

Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers grew its share prices by 10.36 percent on Friday to close at $64.65 apiece as investors resorted to bargain-hunting following two straight days of decline.

Just recently, companies under the healthcare sector, including Hims & Hers Health, Inc. (NYSE:HIMS), were battered by President Donald Trump’s newly signed executive order earlier this week aimed at lowering the costs of drugs in the country. While the initiative would particularly benefit end-consumers, it would, on the other hand, dent drugmakers’ profits and margins.

In its latest earnings release, Hims & Hers Health, Inc. (NYSE:HIMS) said that its net income expanded by 346 percent to $49.5 million from the $11.1 million registered in the same period last year, while revenues soared by 111 percent to $586 million from $278.2 million year-on-year.

The company said that its strong performance underpinned its updated 2025 guidance, with full-year revenues expected to settle between $2.3 billion and $2.4 billion, and the second quarter to end at $530 million to $550 million.

Overall, HIMS ranks 7th on our list of Friday’s top performers. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than HIMS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.